Hydroxymethylquinoxalindioxide as levarage points for otorhinolaryngology

Abstract

Hydroxymethylquinoxaline dioxide, better known as Dioxydin®, holds a special place among topical antimicrobials. The drug has the proven bactericidal action against a wide spectrum of aerobic and anaerobic bacteria, showed good results in otorhinolaryngology as a topical drug to treat bacterial diseases of upper respiratory tract and ear. The authors performed the search for publications among the sources of electronic libraries, such as National Electronic Library (NEB), eLIBRARY, Cyberleninka, Rucont, as well as electronic search engines Pubmed and Google Scholar for the period from 2015 to 2022. The literature analysis resulted in 9 domestic studies, including 6 prospective comparative (4 randomized) studies, two prospective non-comparative studies, and one retrospective descriptive study. The prospective studies involved 400 patients, and the retrospective study analysed the administration in 150 patients. In these studies, hydroxymethylquinoxaline dioxide (Dioxydin®) was used to treat culture-proven infections of upper respiratory tract and ear, both acute and exacerbations of chronic ones. In addition to 0.5% and 1% solutions, which are widely used in ENT practice and need to be prediluted, two new formulations of the drug, fully ready for use, also draws attention: Dioxydin® 2.5 mg/ml, ear drops, and Dioxydin® 0.25 mg/ml, sore throat gargle for topical use. A retrospective review of papers on the use of hydroxymethylquinoxaline dioxide (Dioxydin®) for the topical treatment of upper respiratory tract and ear diseases caused by bacterial agents shows high efficacy, safety and low risk of resistance development. It is promising to conduct studies demonstrating additional therapeutic activity of the Dioxydin®.